Anuh Pharma Board of Directors
Get the latest insights into the leadership at Anuh Pharma. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Manan Jayesh Vadhan | Company Secretary & Compliance Officer |
| Arun Todarwal | Chairman |
| Bipin Shah | Vice Chairman |
| Ritesh Shah | Joint Managing Director |
| Vivek Shah | Joint Managing Director |
| Bharat Shah | Non Executive Director |
| Samir Shah | Non Executive Director |
| Ketan Shah | Non Executive Director |
| Gaurav Shah | Non Executive Director |
| Siddharth Shah | Non Executive Independent Director |
| Pradeep Thakur | Non Executive Independent Director |
| Mita Dixit | Non Executive Independent Director |
| Harmanbhai Tulsibhai Patel | Non Executive Independent Director |
Anuh Pharma FAQs
The board at Anuh Pharma consists of experienced professionals, including Manan Jayesh Vadhan, Arun Todarwal, and others, overseeing the company’s strategic and corporate governance.
Directors at Anuh Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Manan Jayesh Vadhan is the current chairman at Anuh Pharma.
Executive directors at Anuh Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Anuh Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Anuh Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
